Serina Therapeutics (SER) Net Cash Flow (2018 - 2025)

Serina Therapeutics has disclosed Net Cash Flow across 8 years of filings, most recently posting -$5.6 million for Q4 2025.

• In Q4 2025, Net Cash Flow fell 1380.78% year-over-year to -$5.6 million; the TTM figure through Dec 2025 stood at -$647000.0 (up 83.61% YoY), while the FY2025 annual figure was -$647000.0, up 83.61% from the prior year.
• Net Cash Flow came in at -$5.6 million for Q4 2025 at Serina Therapeutics, down from $2.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $8.8 million in Q2 2023 to a low of -$5.6 million in Q4 2025.
• Average Net Cash Flow over 5 years is $145550.0, with a median of $77000.0 recorded in 2021.
• Year-over-year, Net Cash Flow jumped 3368.5% in 2023 and sank 1380.78% in 2025.
• Over 5 years, Net Cash Flow stood at -$147000.0 in 2021, then jumped by 221.77% to $179000.0 in 2022, then sank by 78.77% to $38000.0 in 2023, then soared by 1050.0% to $437000.0 in 2024, then slumped by 1380.78% to -$5.6 million in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$5.6 million in Q4 2025, $2.6 million in Q3 2025, and $1.8 million in Q2 2025.